CAR-CIK Devlopment Service

The Promising of CAR-CIK

Cytokine-induced killer (CIK) cells are a promising immunotherapeutic approach combining the characteristics of T cells and natural killer cells. Stimulated by cytokines like interferon-gamma and anti-CD3 antibodies, CIK cells can proliferate and mature, exhibiting potent anti-tumor activity. Engineered with chimeric antigen receptors (CAR-CIK cells), they have demonstrated significant therapeutic potential, particularly in treating B-cell acute lymphoblastic leukemia. This approach offers advantages over traditional CAR-T and CAR-NK therapies, including reduced allogeneic reactivity and minimal toxicity, making it a promising avenue for future cancer immunotherapy.

Fig.1 Rationale for engineering CIK cells with CAR.¹

CAR-CIK Development Service at Creative Biolabs

Creative Biolabs provides a comprehensive range of CAR-CIK development services to aid in cutting-edge cell treatment development. Our service extends to all stages of development, including accurate target selection and validation, unique CAR construct design and optimization, and rigorous CIK cell isolation, expansion, and engineering. We meticulously characterize each product to assure high levels of safety and efficacy.

In addition, we provide a range of pre-validated targets and CAR designs that are ready for deployment in customers' projects. We also specialize in developing bespoke CAR solutions to meet specific customer demands. Leveraging our powerful platform, we have developed a series of high-quality, ready-to-use CAR-CIK cell products. Backed up by our professional research team, we have confidence in delivering excellent results for each customer in a short turnaround.

Fig.2 CAR-CIK development service process.

Validated Targets for CAR-CIK Development

The emergence of CAR-CIK therapy brings great hope to the field of tumor treatment. The choice of proper targets is critical to the successful development of CAR-CIK cell treatments. Here we provide several well-identified and validated targets to choose from, which include:

Fig.3 Various CAR-CIK development targets.

Available CARs at Creative Biolabs

A well-designed CAR is able to enhance the potency and specificity of CAR-CIK, leading to improved clinical outcomes. Therefore, the design of CAR is a critical step for CAR-CIK development. The following are several CAR formats available at Creative Biolabs, including but not limited to:

Fig.4 Selective CAR formats.²

Advantages

• Deep understanding of CAR cell therapy and immunology.
• State-of-the-art technologies to accelerate development timelines.
• Rigorous quality control to ensure product safety and efficacy.
• Customized services to meet customers' diverse needs.

Published Data

In this research, a novel tandem CAR construct was engineered to target both CD33 and CD146, aiming to enhance T cell cytotoxicity against leukemic cells and their supporting microenvironment. This innovative approach successfully targeted and engaged two distinct cell types within a two-dimensional co-culture environment. The results indicated that the tandem CD33/CD146 CAR Cytokine-Induced Killer (CIK) cells effectively eliminated both target cell lines, KG-1 and TIME, supporting the potential of this dual-targeting strategy for addressing diverse cell populations within the leukemic microenvironment.

Fig.5 Tandem CD33/CD146 CAR CIK cells demonstrated significant killing ability against both target cells.³

As a pioneer in the field of immunotherapy, Creative Biolabs is committed to enhancing CIK therapy by continually researching cutting-edge strategies to address the challenges faced by conventional CIK therapy. For inquiries about our CAR-CIK development service, feel free to reach out to us at any time.

References

1. Rotolo, Ramona, et al. "CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy." International Journal of Molecular Sciences 20.11 (2019): 2839. Distributed under Open Access license CC BY 4.0. The original image was modified by extracting and using a part, and the title was changed to "Rationale for engineering CIK cells with CAR".
2. Hiltensperger, Michael, and Angela M. Krackhardt. "Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells." Frontiers in Immunology 14 (2023): 1121030. Distributed under Open Access license CC BY 4.0. The original image was modified by extracting and using part right, and the title was changed to "Selective CAR formats".
3. Alberti, Gaia, et al. "Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche." Frontiers in Immunology 14 (2023): 1192333. Distributed under Open Access license CC BY 4.0. The original image was modified by extracting and using part C and the title was changed to "Tandem CD33/CD146 CAR CIK cells demonstrated significant killing ability against both target cells".